Amgen Inc.
NASDAQ
Real-time Data
01:30 PM
Day's Range
367.0652 wk Range
269.77Key Statistics
Symbol
AMGN
Name
Amgen Inc.
Currency
USD
Exchange
NASDAQ
High
370.6
Low
367.06
Open
‪369.23‬
Last
‪368.88‬
Market Cap
197.66B
Pe Ratio
‪25.50‬
Volume
45.37K
Average Volume
1.85M
Dividend Yield
‪2.67%‬
Change
2.64
Percent Change
0.72
Timestamp
2026-07-22
Close
368.88
Today Range Start
‪367.06‬
Today Range End
‪370.60‬
52 Week Range Start
‪269.77‬
52 Week Range End
‪391.29‬
Type
Stocks
Country
United States
Compliance - AMGN - Amgen Inc.
Compliance
Status
NON_COMPLIANT
Report Date
2025-02-16
Business Screen
NON_COMPLIANT
Financial Screen
COMPLIANT
Compliant Revenue
‪80.00%‬
Non Compliant Revenue
‪12.00%‬
Questionable Revenue
‪8.00%‬
Securities To Market Cap Ratio
‪1.00%‬
Debt To Market Cap Ratio
‪3.00%‬
Historical Data - AMGN - Amgen Inc.
Historical Data
Market Cap - AMGN - Amgen Inc.
Market Cap
2026-07-20
196.54B
2026-07-17
197.68B
2026-07-16
200.54B
2026-07-15
193.38B
2026-07-14
191.73B
2026-07-13
194.53B
2026-07-10
196.12B
2026-07-09
196.24B
2026-07-08
198.60B
2026-07-07
198.66B
Dividend - AMGN - Amgen Inc.
Dividend
2026-05-15
2.5200
Splits
1999-11-22
2-for-1 split (0.5)
Splits - AMGN - Amgen Inc.
Earnings - AMGN - Amgen Inc.
Earnings
Balance Sheet - AMGN - Amgen Inc.
Balance Sheet
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
 Assets | 90.58B | 91.83B | 97.15B | 65.12B | 61.16B | 62.94B |
| Liabilities | 81.92B | 85.96B | 90.92B | 61.46B | 54.46B | 53.53B |
| Shareholders Equity | 8.65B | 5.87B | 6.23B | 3.66B | 6.70B | 9.40B |
Cash Flow - AMGN - Amgen Inc.
Cash Flow
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Operating Activities | - | - | - | - | - | - |
| Investing Activities | - | - | - | - | - | - |
| Financing Activities | - | - | - | - | - | - |
| End Cash Position | 9.12B | 11.97B | 10.94B | 7.62B | 7.98B | 6.26B |
| Income Tax Paid | - | - | - | - | - | - |
| Interest Paid | - | - | - | - | - | - |
| Free Cash Flow | 8.10B | 10.39B | 7.35B | 8.78B | 8.38B | 9.88B |
Income Statement - AMGN - Amgen Inc.
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 36.75B | 33.42B | 28.19B | 26.32B | 25.97B | 25.42B |
| Cost of Goods | 12.03B | 12.85B | 8.45B | 6.40B | 6.45B | 6.15B |
| Gross Profit | 24.71B | 20.56B | 19.73B | 19.91B | 19.52B | 19.26B |
| Operating Expense | - | - | - | - | - | - |
| Operating Income | 9.08B | 7.25B | 7.89B | 9.56B | 9.14B | 9.13B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 2.65B | 506M | 2.83B | -814M | -1.24B | 256M |
| Pre Tax Income | 8.97B | 4.60B | 7.85B | 7.34B | 6.70B | 8.13B |
| Income Tax | 1.26B | 519M | 1.13B | 794M | 808M | 869M |
| Net Income | 7.71B | 4.09B | 6.71B | 6.55B | 5.89B | 7.26B |
| EPS Basic | 14.33 | 7.62 | 12.56 | 12.18 | 10.34 | 12.4 |
| EPS Diluted | 14.23 | 7.56 | 12.49 | 12.11 | 10.28 | 12.31 |
| Basic Shares Outstanding | 538M | 537M | 535M | 538M | 570M | 586M |
| Diluted Shares Outstanding | 538M | 537M | 535M | 538M | 570M | 586M |
| Ebit | 11.73B | 7.76B | 10.73B | 8.75B | 7.89B | 9.39B |
| Ebitda | 16.89B | 13.35B | 14.80B | 12.16B | 12.80B | 12.99B |
| Net Income Continuous Operations | 7.71B | 4.09B | 6.71B | 6.55B | 5.89B | 7.26B |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
Recommendations - AMGN - Amgen Inc.
Recommendations
Profile - AMGN - Amgen Inc.
Profile
Mic Code
XNGS
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
31.50K
Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on innovative medicines addressing serious illnesses in areas such as oncology, inflammation, cardiovascular disease, bone health, nephrology, and neurology. Key products target conditions like cancer, rheumatoid arthritis, osteoporosis, anemia, and migraines, providing treatments that help manage chronic diseases and improve patient outcomes. Amgen Inc. serves healthcare providers including physicians, clinics, dialysis centers, hospitals, and pharmacies, distributing its portfolio through pharmaceutical wholesale distributors. The company also engages in collaborations, such as partnerships for development and commercialization of specific therapies. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen Inc. plays a vital role in the biotechnology sector by advancing biologic medicines that address unmet medical needs and contribute to global healthcare advancements.
Profile Details
Type
Common Stock
Address
One Amgen Center Drive
City
Thousand Oaks
State
CA
Zip
91320-1799
Country
United States
Phone
805 447 1000
